Neuronal Ceroid Lipofuscinosis Type 8 (CLN8)

Sponsored diagnostic testing programs for Neuronal Ceroid Lipofuscinosis Type 8 (CLN8)

A form of NCL that may present with seizures, cognitive decline, motor impairment, and variable progression. Some individuals exhibit a milder epilepsy-predominant phenotype.

2 programs found for Neuronal Ceroid Lipofuscinosis Type 8 (CLN8)

Programs

2 programs

Invitae® Detect LSDs

Sponsored by
Passage Bio
Neurogene Inc.

Invitae Comprehensive Lysosomal Storage Disorders Panel

The Detect Lysosomal Storage Diseases Program provides no-charge genetic testing for patients in the US or Canada when an LSD is suspected. Eligible patients may present with clinical features, abnormal enzyme studies, positive newborn screens, or relevant family history. Testing through Invitae’s LSD panel can help confirm diagnosis and guide management.

Metabolic

The Lantern Project

Sponsored by
Sanofi

Lysosomal Disorders Testing Pathway

The Lantern Project provides sponsored genetic testing for patients with suspected lysosomal storage diseases (LSDs). LSDs are multisystem disorders caused by impaired lysosomal function and often present with overlapping features. This program supports timely diagnosis by offering testing options for major conditions including Gaucher, Fabry, Pompe, and multiple MPS subtypes.

Metabolic